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Volume 49, Number 5 Abstracts 1361Results: A sample of 100 consecutive SFA occlusions in one of the
centres revealed that only 4% of the lesions were amenable for the study.
The trial was prematurely terminated due to the results of an interim
analysis at the time when 44 patients were recruited: the 1-year primary
patency (excluding technical failures) was 48% for thrupass and 95% for
bypass (p  0.02). The patency difference in favour of surgical bypass
over endovascular thrupass was also sustained after completion of 1-year
follow-up, the primary patencies being 46% and 84% at 1 year with
grossly equilinear life-table curves thereafter (p  0.18), respectively.
The corresponding secondary patencies were 63% and 100% (p  0.05)
when excluding technical failures and 58% and 100% (p  0.02) accord-
ing to intention-to-treat analysis. Secondary outcomes were thus not
analysed.
Conclusion:Treatment of SFA occlusions (TASC IIB and C or Imelda
Ia and II) should be done by PTFE bypass rather than by PTFE thrupass, as
thrupass is connected with worse early outcome. These results represent only
a small category of femoral disease.
The Persistent Sciatic Artery
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Background:A persistent sciatic artery (PSA) is a rare vascular anomaly
with an estimated incidence of 0.03–0.06%. During early embryonic devel-
opment, the sciatic artery usually disappears when the superficial femoral
artery has developed properly. This study aimed to assess the clinical presen-
tation and outcome of a PSA.
Method: A systematic review of all cases of PSA published between
1964 and 2007 was performed.
Results: In this review, 159 PSAs were described in 122 patients. The
mean age at which the PSA was discovered was 57 years, and the incidence
was equally distributed with regards to gender. The majority of PSAs was
unilateral (70%) and of the complete type (79%). Ninety-one patients (80%)
presented with symptoms including intermittent claudication, ischaemia, a
pulsating mass or neurological symptoms. An aneurysm was found in 48%, a
stenosis in 7%, an occlusion of the PSA in 9% and an occlusion of an artery
distal to the PSA in 6% of the subjects. The treatment depended on the
symptoms and classification of the PSA. In nine cases (8%), an amputation
was required eventually.
Conclusion: The PSA is a rare anomaly with a high incidence of
complications including aneurysm formation and ischaemia that may lead to
amputation. Strategies for follow-up could not be deduced from the avail-
able literature.
The Prevalence of Intolerance for Low-Dose Acetylsalicylacid in the
Secondary Prevention of Atherothrombosis
Tournoij E., Peters R.J.G., Langenberg M., Kanhai K.J.K., Moll F.L. Eur J
Vasc Endovasc Surg 2009;xx:xx-xx.
Daily low-dose acetylsalicylacid (ASA) is prescribed to patients withReaders can access EJVES articles at http://intl.eis a range of definitions. We explored the incidence, characteristics and
consequences of symptoms suggestive of ASA intolerance in patients on
low-dose ASA.
General practitioners and specialists in 105 centres were asked to review
their patient files for the last 10 consecutive patients who were prescribed
ASA. Participating patients completed a questionnaire about their current
ASA use (doctors completed the questionnaire together with the patients),
use of co-medication and symptoms suggestive of ASA intolerance.
A total of 947 patients were included in this study. Sixty patients (6.6%)
had ceased ASA treatment, predominantly because of the occurrence of side
effects suspected to be caused by ASA use. A quarter of the patients
concomitantly used an anti-acid agent. Of the 947 patients, 271 (30.6%)
indicated symptoms during ASA intake. The most common symptoms were
related to the gastrointestinal tract (25.1%).
In patients prescribed a low-dose of ASA monotherapy, side effects
suggestive of intolerance are common. More awareness should be created to
detect and treat these symptoms, because the occurrence of side effects is the
most important reason for patients to discontinue ASA treatment.
Combined Aspirin and Cilostazol Treatment is Associated with Re-
duced Platelet Aggregation and Prevention of Exercise-Induced Plate-
let Activation
Cleanthis M., Bhattacharya V., Smout J., Ashour H., Stansby G. Eur J Vasc
Endovasc Surg 2009;xx:xx-xx.
Background: Cilostazol has proven efficacy in increasing walking
distance in claudicants, but it has not been demonstrated to be more
effective than placebo in secondary cardiovascular prevention. The direct
effect of exercise on platelet function remains less well defined. We have
investigated the effect of combination treatment with aspirin and cilostazol
on platelet activity in claudicants subjected to repeated treadmill exercise.
Methods: Nineteen claudicants completed a double-blind, random-
ised, controlled, cross-over trial. Each subject received a 2-week course of
aspirin (75 mg) and placebo and aspirin and cilostazol (100 mg twice daily).
Following each 2-week treatment period, patients participated in a standard-
ised treadmill test (3.2 km h1, 10° incline) walking to maximal claudica-
tion distance. The exercise was repeated thrice in total, and blood was
sampled before and after exercise. Platelet activation wasmeasured using free
platelet counting aggregation, flow cytometry for surface markers of platelet
activation and soluble P-selectin assay.
Results: Compared to aspirin and placebo, combination treatment
with aspirin and cilostazol was associated with reduced arachidonic-acid-
induced platelet aggregation (p  0.01, Wilcoxon signed-rank test). Aspirin
and placebo treatment were associated with elevated P-selectin expression,
platelet-monocyte aggregation and reduced CD42b expression (p  0.05,
Wilcoxon signed-rank test) post-exercise. No difference was seen in sponta-
neous platelet aggregation whilst soluble P-selectin was reduced post-
exercise with combination treatment with aspirin and cilostazol (p  0.05,
Wilcoxon signed-rank test).
Conclusions: Combination treatment with aspirin and cilostazol re-
sults in suppression of platelet activation and reduces the effect of exercise onatherothrombosis frequently to prevent vascular complications. In reports
on complications and side effects of low-dose ASA use in the literature there
platelets. The benefit seen may be a result of cilostazol enhancing the
inhibitory effect of aspirin on the cyclo-oxygenase pathway.lsevierhealth.com/journals/ejvs/default.cfm
